Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Total Current Assets
All assets expected to be converted to cash or used up within one year.
Benitec Biopharma Inc.NASDAQ: BNTC
Total Current Assets · Q3 FY2026 · quarter ended Mar 2026
Total current assets rises 78.8% from a year ago
Total current assets stood at $186.02M at the end of Q3 FY2026, up 78.8% from a year earlier and down 1.9% from the prior quarter. Over 3 fiscal years it compounded at +173.4% a year.
Context
- Total current assets amounted to 99.5% of total assets at the end of Q3 FY2026, up 0.6 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +78.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 98.52M USD
- Year-over-year change
- +90.7%
- 4-year CAGR
- +47.9%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 98.52M | +90.7% |
| FY2024 | 2024-06-30 | 51.67M | +1285.7% |
| FY2023 | 2023-06-30 | 3.73M | -22.6% |
| FY2022 | 2022-06-30 | 4.82M | -76.6% |
| FY2021 | 2021-06-30 | 20.61M | — |
Total Current Assets vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 total current assets of $186.02M is the 5th highest of the 10 companies compared; the peer median is $134.96M.
- Its year-over-year change of +78.8% is the highest of 10, against a peer median of -12.3%.
- Total current assets amounts to 99.5% of total assets for BNTC, versus a peer median of 67.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $396.79M | +26.6% | -2.2% | 93.8% | |
| Mar 2026 | $368.84M | -40.1% | +0.8% | 70.0% | |
| Dec 2025 | $305.02M | -21.0% | -7.6% | 57.0% | |
| Mar 2026 | $246.75M | -16.8% | +47.5% | 93.8% | |
| Mar 2026 | $186.02M | +78.8% | +173.4% | 99.5% | |
| Mar 2026 | $134.96M | -44.2% | -21.1% | 63.3% | |
| Mar 2026 | $118.75M | +4.9% | +24.2% | 43.7% | |
| Mar 2026 | $56.16M | +12.4% | -0.5% | 51.3% | |
| Mar 2026 | $38.55M | -12.3% | -37.2% | 67.7% | |
| Mar 2026 | $15.69M | +69.0% | -1.8% | 99.6% | |
| Peer median (excluding BNTC) | $134.96M | -12.3% | -1.8% | 67.7% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.